This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-106b-5p | ABCD2 | 2.81 | 0 | -2.82 | 0.00416 | MirTarget | -0.5 | 2.0E-5 | NA | |
2 | hsa-miR-106b-5p | ADAM19 | 2.81 | 0 | 0.44 | 0.52629 | mirMAP | -0.18 | 0.03423 | NA | |
3 | hsa-miR-106b-5p | ADAM9 | 2.81 | 0 | 0.33 | 0.49553 | miRNATAP | -0.13 | 0.02564 | NA | |
4 | hsa-miR-106b-5p | ADAMTS5 | 2.81 | 0 | -6.22 | 0 | miRNATAP | -0.56 | 0 | NA | |
5 | hsa-miR-106b-5p | ADRA2A | 2.81 | 0 | -3.42 | 0.00512 | miRNATAP | -0.75 | 0 | NA | |
6 | hsa-miR-106b-5p | AHNAK | 2.81 | 0 | -1.19 | 0.03091 | miRNATAP | -0.28 | 2.0E-5 | NA | |
7 | hsa-miR-106b-5p | AKAP11 | 2.81 | 0 | -0.61 | 0.12508 | miRNAWalker2 validate | -0.19 | 5.0E-5 | NA | |
8 | hsa-miR-106b-5p | AKAP13 | 2.81 | 0 | -1.49 | 0.00023 | MirTarget; mirMAP; miRNATAP | -0.24 | 0 | NA | |
9 | hsa-miR-106b-5p | AKT3 | 2.81 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.41 | 1.0E-5 | NA | |
10 | hsa-miR-106b-5p | ANK2 | 2.81 | 0 | -5.41 | 0 | MirTarget; miRNATAP | -0.77 | 0 | NA | |
11 | hsa-miR-106b-5p | ANKRD12 | 2.81 | 0 | -0.49 | 0.18892 | MirTarget | -0.11 | 0.02006 | NA | |
12 | hsa-miR-106b-5p | ANKRD29 | 2.81 | 0 | -2.36 | 0.04103 | MirTarget | -0.35 | 0.01138 | NA | |
13 | hsa-miR-106b-5p | ANKRD50 | 2.81 | 0 | -0.02 | 0.97181 | MirTarget; miRNATAP | -0.2 | 0.00277 | NA | |
14 | hsa-miR-106b-5p | ANO6 | 2.81 | 0 | -1.42 | 0.00017 | MirTarget | -0.22 | 0 | NA | |
15 | hsa-miR-106b-5p | APBB2 | 2.81 | 0 | -1.53 | 0.00158 | MirTarget; miRNATAP | -0.12 | 0.0483 | NA | |
16 | hsa-miR-106b-5p | AR | 2.81 | 0 | -4.57 | 0.00169 | mirMAP | -0.67 | 0.00014 | NA | |
17 | hsa-miR-106b-5p | ARHGAP1 | 2.81 | 0 | -0.85 | 0.00369 | MirTarget; miRNATAP | -0.18 | 0 | NA | |
18 | hsa-miR-106b-5p | ARHGAP23 | 2.81 | 0 | 0.12 | 0.89085 | mirMAP | -0.35 | 0.00083 | NA | |
19 | hsa-miR-106b-5p | ARHGEF3 | 2.81 | 0 | -1 | 0.016 | MirTarget; miRNATAP | -0.16 | 0.00129 | NA | |
20 | hsa-miR-106b-5p | ARID4A | 2.81 | 0 | -0.65 | 0.04997 | MirTarget; miRNATAP | -0.12 | 0.00297 | NA | |
21 | hsa-miR-106b-5p | ASH1L | 2.81 | 0 | -0.25 | 0.53283 | miRNATAP | -0.1 | 0.03313 | NA | |
22 | hsa-miR-106b-5p | ASPA | 2.81 | 0 | -5.53 | 0 | mirMAP | -0.57 | 7.0E-5 | NA | |
23 | hsa-miR-106b-5p | ATP1A2 | 2.81 | 0 | -6.92 | 0 | MirTarget; miRNATAP | -0.8 | 0 | NA | |
24 | hsa-miR-106b-5p | BACH1 | 2.81 | 0 | 0.1 | 0.82342 | mirMAP | -0.17 | 0.00135 | NA | |
25 | hsa-miR-106b-5p | BCAS1 | 2.81 | 0 | -0.07 | 0.96835 | mirMAP | -0.48 | 0.0168 | NA | |
26 | hsa-miR-106b-5p | BCL9L | 2.81 | 0 | -0.12 | 0.78985 | mirMAP | -0.17 | 0.00113 | NA | |
27 | hsa-miR-106b-5p | BHLHE41 | 2.81 | 0 | -1.22 | 0.21729 | miRNATAP | -0.45 | 0.00016 | NA | |
28 | hsa-miR-106b-5p | BICD2 | 2.81 | 0 | 0.86 | 0.21413 | MirTarget; miRNATAP | -0.18 | 0.03129 | NA | |
29 | hsa-miR-106b-5p | BMPR2 | 2.81 | 0 | -1.13 | 0.00109 | MirTarget; miRNATAP | -0.12 | 0.00443 | NA | |
30 | hsa-miR-106b-5p | BNC2 | 2.81 | 0 | -6.04 | 0 | miRNATAP | -0.69 | 0 | NA | |
31 | hsa-miR-106b-5p | BNIP3L | 2.81 | 0 | -0.64 | 0.09912 | MirTarget | -0.1 | 0.02447 | NA | |
32 | hsa-miR-106b-5p | BTG2 | 2.81 | 0 | -1.97 | 0.00034 | miRNATAP | -0.19 | 0.00464 | NA | |
33 | hsa-miR-106b-5p | BTN3A3 | 2.81 | 0 | -0.66 | 0.3546 | miRNAWalker2 validate | -0.2 | 0.01786 | NA | |
34 | hsa-miR-106b-5p | C14orf28 | 2.81 | 0 | -2.36 | 0 | miRNATAP | -0.24 | 0 | NA | |
35 | hsa-miR-106b-5p | C3orf70 | 2.81 | 0 | -3.41 | 0.0008 | miRNATAP | -0.44 | 0.00035 | NA | |
36 | hsa-miR-106b-5p | CALD1 | 2.81 | 0 | -3.83 | 0 | miRNATAP | -0.43 | 0 | NA | |
37 | hsa-miR-106b-5p | CAMK2N1 | 2.81 | 0 | -1.94 | 0.07697 | miRNATAP | -0.32 | 0.0156 | NA | |
38 | hsa-miR-106b-5p | CAMK4 | 2.81 | 0 | 0.83 | 0.3952 | mirMAP | -0.25 | 0.03668 | NA | |
39 | hsa-miR-106b-5p | CAPN5 | 2.81 | 0 | -1.42 | 0.21891 | mirMAP | -0.32 | 0.02438 | NA | |
40 | hsa-miR-106b-5p | CASC4 | 2.81 | 0 | -1.31 | 0.00161 | MirTarget | -0.13 | 0.00793 | NA | |
41 | hsa-miR-106b-5p | CAV1 | 2.81 | 0 | -3.38 | 0.00041 | miRNATAP | -0.34 | 0.00331 | NA | |
42 | hsa-miR-106b-5p | CAV2 | 2.81 | 0 | -1.14 | 0.15869 | mirMAP | -0.22 | 0.02621 | NA | |
43 | hsa-miR-106b-5p | CBX7 | 2.81 | 0 | -3.22 | 0 | mirMAP | -0.25 | 8.0E-5 | NA | |
44 | hsa-miR-106b-5p | CCBE1 | 2.81 | 0 | -5.42 | 0.00228 | mirMAP | -0.45 | 0.0393 | NA | |
45 | hsa-miR-106b-5p | CCND2 | 2.81 | 0 | -2.81 | 0.0014 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.31 | 0.00374 | NA | |
46 | hsa-miR-106b-5p | CCNG2 | 2.81 | 0 | -0.75 | 0.10471 | MirTarget; miRNATAP | -0.14 | 0.01499 | NA | |
47 | hsa-miR-106b-5p | CD28 | 2.81 | 0 | 0.13 | 0.8756 | mirMAP | -0.21 | 0.04267 | NA | |
48 | hsa-miR-106b-5p | CD34 | 2.81 | 0 | -4.42 | 0 | miRNAWalker2 validate | -0.36 | 0 | NA | |
49 | hsa-miR-106b-5p | CD69 | 2.81 | 0 | -0.72 | 0.42333 | miRNATAP | -0.41 | 0.00015 | NA | |
50 | hsa-miR-106b-5p | CDKN1A | 2.81 | 0 | 0.58 | 0.35758 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.17 | 0.02713 | NA | |
51 | hsa-miR-106b-5p | CELF2 | 2.81 | 0 | -2.48 | 0.00126 | miRNATAP | -0.32 | 0.00066 | NA | |
52 | hsa-miR-106b-5p | CES2 | 2.81 | 0 | 0.44 | 0.44746 | miRNAWalker2 validate | -0.22 | 0.00153 | NA | |
53 | hsa-miR-106b-5p | CHD9 | 2.81 | 0 | -0.3 | 0.4758 | MirTarget; miRNATAP | -0.21 | 4.0E-5 | NA | |
54 | hsa-miR-106b-5p | CLDN16 | 2.81 | 0 | 1.66 | 0.2236 | mirMAP | -0.39 | 0.01828 | NA | |
55 | hsa-miR-106b-5p | CLIP4 | 2.81 | 0 | -0.83 | 0.29386 | MirTarget | -0.27 | 0.00536 | NA | |
56 | hsa-miR-106b-5p | CNTNAP3 | 2.81 | 0 | 0.85 | 0.50149 | MirTarget | -0.36 | 0.01812 | NA | |
57 | hsa-miR-106b-5p | COL1A1 | 2.81 | 0 | -1.84 | 0.04283 | mirMAP | -0.53 | 0 | NA | |
58 | hsa-miR-106b-5p | COL8A2 | 2.81 | 0 | -0.62 | 0.47257 | mirMAP | -0.49 | 0 | NA | |
59 | hsa-miR-106b-5p | CORO2B | 2.81 | 0 | -3.89 | 0.0006 | MirTarget; miRNATAP | -0.52 | 0.00016 | NA | |
60 | hsa-miR-106b-5p | CPEB3 | 2.81 | 0 | -0.08 | 0.87798 | miRNATAP | -0.24 | 0.00011 | NA | |
61 | hsa-miR-106b-5p | CPEB4 | 2.81 | 0 | -0.65 | 0.23946 | mirMAP | -0.29 | 1.0E-5 | NA | |
62 | hsa-miR-106b-5p | CRY2 | 2.81 | 0 | -2.49 | 0 | MirTarget; miRNATAP | -0.17 | 1.0E-5 | NA | |
63 | hsa-miR-106b-5p | CRYBG3 | 2.81 | 0 | -0.15 | 0.82713 | MirTarget; miRNATAP | -0.22 | 0.00648 | NA | |
64 | hsa-miR-106b-5p | CSF1 | 2.81 | 0 | -1.1 | 0.12732 | miRNATAP | -0.26 | 0.00324 | NA | |
65 | hsa-miR-106b-5p | CSGALNACT1 | 2.81 | 0 | -1.68 | 0.01886 | MirTarget | -0.24 | 0.00646 | NA | |
66 | hsa-miR-106b-5p | CTSK | 2.81 | 0 | -3.32 | 1.0E-5 | MirTarget | -0.74 | 0 | NA | |
67 | hsa-miR-106b-5p | CXorf36 | 2.81 | 0 | -4.77 | 0 | mirMAP | -0.5 | 0 | NA | |
68 | hsa-miR-106b-5p | CYBRD1 | 2.81 | 0 | -3.33 | 0 | MirTarget | -0.31 | 0.00023 | NA | |
69 | hsa-miR-106b-5p | CYP2U1 | 2.81 | 0 | -2.33 | 8.0E-5 | MirTarget | -0.18 | 0.01186 | NA | |
70 | hsa-miR-106b-5p | DAB2 | 2.81 | 0 | -2.28 | 0.00051 | MirTarget; miRNATAP | -0.37 | 0 | 26769181 | The expression of the miR-106b target gene DAB2 in human cervical tissues and cell lines were measured by qRT-PCR western blot and immunohistochemistry; DAB2 a predicted target gene of miR-106b was inhibited by TGF-β1 partly through miR-106b and was involved in TGF-β1-induced cervical cancer cell migration; The expression of DAB2 was low in cervical cancer tissues and negatively correlated with miR-106b expression |
71 | hsa-miR-106b-5p | DIP2C | 2.81 | 0 | -1.71 | 0.00051 | miRNATAP | -0.14 | 0.01701 | NA | |
72 | hsa-miR-106b-5p | DIXDC1 | 2.81 | 0 | -4.24 | 0 | mirMAP | -0.34 | 4.0E-5 | NA | |
73 | hsa-miR-106b-5p | DLC1 | 2.81 | 0 | -3.66 | 0 | miRNATAP | -0.52 | 0 | 26223867 | MicroRNA 106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1; Moreover we identify DLC1 as a direct target of miR-106b reveal its expression to be inversely correlated with miR-106b in CRC samples and show that its re-introduction reverses miR-106b-induced CRC cell migration and invasion; Furthermore survival analyses showed the patients with high mi-106b/low DLC1 had shorter overall survival OS and disease-free survival DFS rates and confirmed miR-106b may be an independent prognostic factor for OS and DFS in CRC patients; Our findings indicate that miR-106b promotes CRC cell migration and invasion by targeting DLC1 |
74 | hsa-miR-106b-5p | DMD | 2.81 | 0 | -4.18 | 0.00037 | mirMAP | -0.42 | 0.00365 | NA | |
75 | hsa-miR-106b-5p | DOCK4 | 2.81 | 0 | -2.11 | 0.00043 | MirTarget | -0.16 | 0.0257 | NA | |
76 | hsa-miR-106b-5p | DPYD | 2.81 | 0 | -0.3 | 0.70769 | MirTarget | -0.41 | 2.0E-5 | NA | |
77 | hsa-miR-106b-5p | DSTYK | 2.81 | 0 | -0.94 | 0.00369 | miRNATAP | -0.11 | 0.0069 | NA | |
78 | hsa-miR-106b-5p | EDA2R | 2.81 | 0 | -4.27 | 7.0E-5 | MirTarget | -0.52 | 7.0E-5 | NA | |
79 | hsa-miR-106b-5p | EEA1 | 2.81 | 0 | -0.24 | 0.59857 | MirTarget; miRNATAP | -0.25 | 1.0E-5 | NA | |
80 | hsa-miR-106b-5p | EGR2 | 2.81 | 0 | -1.39 | 0.09323 | MirTarget; miRNATAP | -0.33 | 0.0011 | NA | |
81 | hsa-miR-106b-5p | ELAVL2 | 2.81 | 0 | 1.95 | 0.32272 | MirTarget; miRNATAP | -0.51 | 0.03133 | NA | |
82 | hsa-miR-106b-5p | ELK3 | 2.81 | 0 | -0.79 | 0.2934 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.36 | 6.0E-5 | NA | |
83 | hsa-miR-106b-5p | ENPP1 | 2.81 | 0 | -5.25 | 1.0E-5 | mirMAP | -0.39 | 0.00587 | NA | |
84 | hsa-miR-106b-5p | ENTPD1 | 2.81 | 0 | -1.65 | 0 | mirMAP | -0.19 | 0 | NA | |
85 | hsa-miR-106b-5p | EPB41L1 | 2.81 | 0 | 0.13 | 0.82668 | mirMAP | -0.23 | 0.00129 | NA | |
86 | hsa-miR-106b-5p | EPHA4 | 2.81 | 0 | -1.24 | 0.2429 | miRNATAP | -0.38 | 0.00333 | NA | |
87 | hsa-miR-106b-5p | EPHA7 | 2.81 | 0 | -3.77 | 0.02027 | miRNATAP | -0.4 | 0.04095 | NA | |
88 | hsa-miR-106b-5p | ETV1 | 2.81 | 0 | -1.44 | 0.12087 | MirTarget; miRNATAP | -0.43 | 0.00012 | NA | |
89 | hsa-miR-106b-5p | EZH1 | 2.81 | 0 | -1.8 | 0 | MirTarget; miRNATAP | -0.14 | 7.0E-5 | NA | |
90 | hsa-miR-106b-5p | FAM102A | 2.81 | 0 | -0.08 | 0.85761 | miRNATAP | -0.16 | 0.00315 | NA | |
91 | hsa-miR-106b-5p | FAT3 | 2.81 | 0 | -3.48 | 0.01525 | mirMAP | -0.63 | 0.00026 | NA | |
92 | hsa-miR-106b-5p | FAT4 | 2.81 | 0 | -3.6 | 0.00012 | MirTarget; miRNATAP | -0.59 | 0 | NA | |
93 | hsa-miR-106b-5p | FBXL3 | 2.81 | 0 | -1.14 | 0.00089 | miRNATAP | -0.14 | 0.00054 | NA | |
94 | hsa-miR-106b-5p | FBXL5 | 2.81 | 0 | -0.86 | 0.00474 | miRNATAP | -0.11 | 0.00388 | NA | |
95 | hsa-miR-106b-5p | FBXO3 | 2.81 | 0 | -0.64 | 0.06434 | mirMAP | -0.13 | 0.00173 | NA | |
96 | hsa-miR-106b-5p | FCHO2 | 2.81 | 0 | -0.58 | 0.15656 | miRNATAP | -0.18 | 0.00022 | NA | |
97 | hsa-miR-106b-5p | FGD5 | 2.81 | 0 | -3.68 | 0 | MirTarget; miRNATAP | -0.45 | 0 | NA | |
98 | hsa-miR-106b-5p | FGFR1 | 2.81 | 0 | -3.68 | 0.00012 | mirMAP | -0.33 | 0.00494 | NA | |
99 | hsa-miR-106b-5p | FGL2 | 2.81 | 0 | -1.48 | 0.10265 | MirTarget | -0.39 | 0.00032 | NA | |
100 | hsa-miR-106b-5p | FHL2 | 2.81 | 0 | -1.28 | 0.09059 | mirMAP | -0.22 | 0.01819 | NA | |
101 | hsa-miR-106b-5p | FIBIN | 2.81 | 0 | -3.85 | 0.00528 | MirTarget | -0.97 | 0 | NA | |
102 | hsa-miR-106b-5p | FMN1 | 2.81 | 0 | 1.87 | 0.076 | mirMAP | -0.31 | 0.0155 | NA | |
103 | hsa-miR-106b-5p | FNBP1 | 2.81 | 0 | -2.26 | 0 | miRNAWalker2 validate | -0.17 | 0.0007 | NA | |
104 | hsa-miR-106b-5p | FNDC3A | 2.81 | 0 | -1.17 | 0.01366 | MirTarget; miRNATAP | -0.15 | 0.00984 | NA | |
105 | hsa-miR-106b-5p | FOXN3 | 2.81 | 0 | -1.07 | 0.00864 | miRNATAP | -0.16 | 0.00104 | NA | |
106 | hsa-miR-106b-5p | FRMD6 | 2.81 | 0 | -1.61 | 0.08207 | MirTarget; miRNATAP | -0.43 | 0.0001 | NA | |
107 | hsa-miR-106b-5p | FTO | 2.81 | 0 | -1.07 | 0.00045 | mirMAP | -0.11 | 0.00324 | NA | |
108 | hsa-miR-106b-5p | FYCO1 | 2.81 | 0 | -1.65 | 6.0E-5 | MirTarget | -0.22 | 1.0E-5 | NA | |
109 | hsa-miR-106b-5p | FYN | 2.81 | 0 | -2.7 | 5.0E-5 | miRNATAP | -0.17 | 0.03506 | NA | |
110 | hsa-miR-106b-5p | GAB1 | 2.81 | 0 | -1.63 | 0.00014 | MirTarget; miRNATAP | -0.18 | 0.00042 | NA | |
111 | hsa-miR-106b-5p | GAS7 | 2.81 | 0 | -3.05 | 0.00021 | mirMAP | -0.61 | 0 | NA | |
112 | hsa-miR-106b-5p | GBP4 | 2.81 | 0 | 0.55 | 0.60015 | mirMAP | -0.48 | 0.00014 | NA | |
113 | hsa-miR-106b-5p | GCNT4 | 2.81 | 0 | -0.7 | 0.43866 | MirTarget | -0.34 | 0.00167 | NA | |
114 | hsa-miR-106b-5p | GFRA1 | 2.81 | 0 | -6.72 | 0 | mirMAP | -1.12 | 0 | NA | |
115 | hsa-miR-106b-5p | GNE | 2.81 | 0 | -1.11 | 0.12265 | mirMAP | -0.2 | 0.02358 | NA | |
116 | hsa-miR-106b-5p | GPM6A | 2.81 | 0 | -8.84 | 0 | miRNAWalker2 validate | -0.74 | 0 | NA | |
117 | hsa-miR-106b-5p | GPR137B | 2.81 | 0 | -0.66 | 0.11072 | miRNATAP | -0.17 | 0.00045 | NA | |
118 | hsa-miR-106b-5p | GREM2 | 2.81 | 0 | -5.65 | 0 | mirMAP | -0.69 | 0 | NA | |
119 | hsa-miR-106b-5p | HAS2 | 2.81 | 0 | -0.87 | 0.54181 | MirTarget | -0.42 | 0.01427 | NA | |
120 | hsa-miR-106b-5p | HEG1 | 2.81 | 0 | -1.11 | 0.15703 | miRNATAP | -0.49 | 0 | NA | |
121 | hsa-miR-106b-5p | HLA-DOA | 2.81 | 0 | -1.19 | 0.28119 | mirMAP | -0.35 | 0.00821 | NA | |
122 | hsa-miR-106b-5p | HLF | 2.81 | 0 | -4.18 | 0.00043 | MirTarget; miRNATAP | -0.45 | 0.00195 | NA | |
123 | hsa-miR-106b-5p | IFNAR2 | 2.81 | 0 | -0.05 | 0.87658 | miRNAWalker2 validate | -0.1 | 0.01118 | NA | |
124 | hsa-miR-106b-5p | IKZF2 | 2.81 | 0 | 2.49 | 0.00195 | mirMAP; miRNATAP | -0.31 | 0.00125 | NA | |
125 | hsa-miR-106b-5p | IKZF4 | 2.81 | 0 | -1.11 | 0.00184 | MirTarget; miRNATAP | -0.11 | 0.00932 | NA | |
126 | hsa-miR-106b-5p | IRF9 | 2.81 | 0 | 0.81 | 0.07531 | miRNAWalker2 validate | -0.13 | 0.01622 | NA | |
127 | hsa-miR-106b-5p | ISM1 | 2.81 | 0 | 0.01 | 0.99522 | miRNATAP | -0.55 | 0 | NA | |
128 | hsa-miR-106b-5p | JAK1 | 2.81 | 0 | -0.61 | 0.04091 | miRNAWalker2 validate; MirTarget | -0.18 | 0 | NA | |
129 | hsa-miR-106b-5p | JAM3 | 2.81 | 0 | -4.56 | 0 | mirMAP | -0.53 | 0 | NA | |
130 | hsa-miR-106b-5p | JAZF1 | 2.81 | 0 | -3.33 | 0 | MirTarget; miRNATAP | -0.23 | 0.00186 | NA | |
131 | hsa-miR-106b-5p | KANK1 | 2.81 | 0 | -1.88 | 0.00218 | mirMAP | -0.3 | 5.0E-5 | NA | |
132 | hsa-miR-106b-5p | KANK2 | 2.81 | 0 | -3.73 | 0 | miRNAWalker2 validate; mirMAP | -0.36 | 0 | NA | |
133 | hsa-miR-106b-5p | KAT2B | 2.81 | 0 | -1.07 | 0.03591 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.28 | 1.0E-5 | NA | |
134 | hsa-miR-106b-5p | KATNAL1 | 2.81 | 0 | -1.63 | 0.00107 | miRNAWalker2 validate; MirTarget | -0.19 | 0.00183 | NA | |
135 | hsa-miR-106b-5p | KCND3 | 2.81 | 0 | -1.6 | 0.24861 | mirMAP | -0.82 | 0 | NA | |
136 | hsa-miR-106b-5p | KCNE4 | 2.81 | 0 | -4.84 | 0 | miRNATAP | -0.54 | 0 | NA | |
137 | hsa-miR-106b-5p | KCNMA1 | 2.81 | 0 | -6.35 | 0 | miRNATAP | -0.7 | 0 | NA | |
138 | hsa-miR-106b-5p | KDSR | 2.81 | 0 | -0.72 | 0.0333 | mirMAP | -0.1 | 0.01237 | NA | |
139 | hsa-miR-106b-5p | KIAA0355 | 2.81 | 0 | -1.3 | 0.00011 | mirMAP | -0.12 | 0.00378 | NA | |
140 | hsa-miR-106b-5p | KIAA0513 | 2.81 | 0 | -0.31 | 0.60371 | MirTarget; miRNATAP | -0.22 | 0.0019 | NA | |
141 | hsa-miR-106b-5p | KLF9 | 2.81 | 0 | -3.7 | 0 | MirTarget; miRNATAP | -0.39 | 0 | NA | |
142 | hsa-miR-106b-5p | KLHL20 | 2.81 | 0 | -0.29 | 0.43362 | MirTarget; miRNATAP | -0.11 | 0.01766 | NA | |
143 | hsa-miR-106b-5p | KLHL28 | 2.81 | 0 | -0.13 | 0.76115 | miRNATAP | -0.12 | 0.01878 | NA | |
144 | hsa-miR-106b-5p | KLHL3 | 2.81 | 0 | -2.04 | 0.00444 | mirMAP | -0.18 | 0.03814 | NA | |
145 | hsa-miR-106b-5p | KLHL6 | 2.81 | 0 | 0.99 | 0.19763 | mirMAP | -0.21 | 0.02308 | NA | |
146 | hsa-miR-106b-5p | LAT2 | 2.81 | 0 | 0.48 | 0.42455 | mirMAP | -0.21 | 0.0036 | NA | |
147 | hsa-miR-106b-5p | LDB3 | 2.81 | 0 | -4.98 | 0 | mirMAP | -0.4 | 0.00038 | NA | |
148 | hsa-miR-106b-5p | LMO3 | 2.81 | 0 | -6.72 | 3.0E-5 | MirTarget; miRNATAP | -1.12 | 0 | NA | |
149 | hsa-miR-106b-5p | LRFN5 | 2.81 | 0 | -4.64 | 0.00014 | miRNATAP | -0.96 | 0 | NA | |
150 | hsa-miR-106b-5p | LRRN4CL | 2.81 | 0 | -6 | 0 | mirMAP | -0.84 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TISSUE DEVELOPMENT | 67 | 1518 | 9.376e-13 | 4.363e-09 |
2 | REGULATION OF CELL DIFFERENTIATION | 64 | 1492 | 1.161e-11 | 2.702e-08 |
3 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 41 | 788 | 3.716e-10 | 4.322e-07 |
4 | CIRCULATORY SYSTEM DEVELOPMENT | 41 | 788 | 3.716e-10 | 4.322e-07 |
5 | INTRACELLULAR SIGNAL TRANSDUCTION | 62 | 1572 | 7.786e-10 | 7.246e-07 |
6 | MUSCLE STRUCTURE DEVELOPMENT | 28 | 432 | 2.523e-09 | 1.957e-06 |
7 | MUSCLE TISSUE DEVELOPMENT | 22 | 275 | 3.075e-09 | 2.044e-06 |
8 | CELL DEVELOPMENT | 56 | 1426 | 6.954e-09 | 3.595e-06 |
9 | REGULATION OF CELL DEVELOPMENT | 40 | 836 | 6.79e-09 | 3.595e-06 |
10 | REGULATION OF MAPK CASCADE | 34 | 660 | 1.68e-08 | 7.106e-06 |
11 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 60 | 1618 | 1.53e-08 | 7.106e-06 |
12 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 61 | 1672 | 2.064e-08 | 8.005e-06 |
13 | NEUROGENESIS | 54 | 1402 | 2.598e-08 | 9.3e-06 |
14 | REGULATION OF KINASE ACTIVITY | 37 | 776 | 2.862e-08 | 9.511e-06 |
15 | POSITIVE REGULATION OF CELL COMMUNICATION | 57 | 1532 | 3.341e-08 | 1.036e-05 |
16 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 63 | 1784 | 3.894e-08 | 1.132e-05 |
17 | REGULATION OF PROTEIN MODIFICATION PROCESS | 61 | 1710 | 4.664e-08 | 1.276e-05 |
18 | VASCULATURE DEVELOPMENT | 27 | 469 | 5.836e-08 | 1.509e-05 |
19 | POSITIVE REGULATION OF GENE EXPRESSION | 61 | 1733 | 7.518e-08 | 1.522e-05 |
20 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 46 | 1135 | 7.402e-08 | 1.522e-05 |
21 | NEURON DIFFERENTIATION | 39 | 874 | 6.883e-08 | 1.522e-05 |
22 | POSITIVE REGULATION OF CELL DEVELOPMENT | 27 | 472 | 6.646e-08 | 1.522e-05 |
23 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 36 | 771 | 7.523e-08 | 1.522e-05 |
24 | REGULATION OF NEURON DIFFERENTIATION | 29 | 554 | 1.429e-07 | 2.77e-05 |
25 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 58 | 1656 | 1.978e-07 | 3.681e-05 |
26 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 38 | 876 | 2.102e-07 | 3.762e-05 |
27 | POSITIVE REGULATION OF MAPK CASCADE | 26 | 470 | 2.251e-07 | 3.852e-05 |
28 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 45 | 1142 | 2.318e-07 | 3.852e-05 |
29 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 64 | 1929 | 2.898e-07 | 4.214e-05 |
30 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 42 | 1036 | 2.878e-07 | 4.214e-05 |
31 | KIDNEY EPITHELIUM DEVELOPMENT | 13 | 125 | 2.753e-07 | 4.214e-05 |
32 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 42 | 1036 | 2.878e-07 | 4.214e-05 |
33 | UROGENITAL SYSTEM DEVELOPMENT | 20 | 299 | 3.074e-07 | 4.334e-05 |
34 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 34 | 750 | 3.517e-07 | 4.813e-05 |
35 | POSITIVE REGULATION OF KINASE ACTIVITY | 26 | 482 | 3.655e-07 | 4.858e-05 |
36 | BLOOD VESSEL MORPHOGENESIS | 22 | 364 | 4.489e-07 | 5.803e-05 |
37 | EPITHELIUM DEVELOPMENT | 39 | 945 | 5.096e-07 | 6.409e-05 |
38 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 60 | 1791 | 5.329e-07 | 6.525e-05 |
39 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 20 | 312 | 6.034e-07 | 7.199e-05 |
40 | HEART DEVELOPMENT | 25 | 466 | 6.818e-07 | 7.931e-05 |
41 | REGULATION OF SYSTEM PROCESS | 26 | 507 | 9.504e-07 | 0.0001079 |
42 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 35 | 823 | 1.035e-06 | 0.0001146 |
43 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 52 | 1492 | 1.086e-06 | 0.0001175 |
44 | NEURON PROJECTION DEVELOPMENT | 27 | 545 | 1.135e-06 | 0.00012 |
45 | ACTIN FILAMENT BASED PROCESS | 24 | 450 | 1.27e-06 | 0.0001313 |
46 | REGULATION OF TRANSFERASE ACTIVITY | 38 | 946 | 1.387e-06 | 0.0001403 |
47 | ORGAN MORPHOGENESIS | 35 | 841 | 1.69e-06 | 0.0001673 |
48 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 52 | 1518 | 1.809e-06 | 0.0001753 |
49 | POSITIVE REGULATION OF NEURON DIFFERENTIATION | 19 | 306 | 1.858e-06 | 0.0001764 |
50 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 32 | 740 | 2.171e-06 | 0.000202 |
51 | NEURON PROJECTION MORPHOGENESIS | 22 | 402 | 2.335e-06 | 0.0002131 |
52 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 16 | 229 | 2.703e-06 | 0.0002288 |
53 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 23 | 437 | 2.65e-06 | 0.0002288 |
54 | MEMBRANE DEPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 5 | 14 | 2.689e-06 | 0.0002288 |
55 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 24 | 470 | 2.704e-06 | 0.0002288 |
56 | REGULATION OF CHEMOTAXIS | 14 | 180 | 3.296e-06 | 0.0002739 |
57 | NEURON DEVELOPMENT | 30 | 687 | 3.769e-06 | 0.0003024 |
58 | REGULATION OF CATION TRANSMEMBRANE TRANSPORT | 15 | 208 | 3.764e-06 | 0.0003024 |
59 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 30 | 689 | 3.993e-06 | 0.0003149 |
60 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 48 | 1395 | 4.219e-06 | 0.0003218 |
61 | MUSCLE CELL DIFFERENTIATION | 16 | 237 | 4.208e-06 | 0.0003218 |
62 | POSITIVE REGULATION OF LOCOMOTION | 22 | 420 | 4.731e-06 | 0.0003551 |
63 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 13 | 162 | 5.245e-06 | 0.0003874 |
64 | RESPONSE TO ENDOGENOUS STIMULUS | 49 | 1450 | 5.429e-06 | 0.0003947 |
65 | REGULATION OF CELL ADHESION | 28 | 629 | 5.61e-06 | 0.0003955 |
66 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 38 | 1004 | 5.601e-06 | 0.0003955 |
67 | CARDIAC MUSCLE TISSUE DEVELOPMENT | 12 | 140 | 6.145e-06 | 0.0004267 |
68 | EPITHELIAL CELL DIFFERENTIATION | 24 | 495 | 6.527e-06 | 0.0004466 |
69 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 57 | 1805 | 6.669e-06 | 0.0004497 |
70 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 19 | 337 | 7.534e-06 | 0.0004869 |
71 | CELLULAR COMPONENT MORPHOGENESIS | 35 | 900 | 7.532e-06 | 0.0004869 |
72 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 20 | 368 | 7.484e-06 | 0.0004869 |
73 | CELL PROJECTION ORGANIZATION | 35 | 902 | 7.9e-06 | 0.0005036 |
74 | REGULATION OF TRANSPORTER ACTIVITY | 14 | 198 | 9.925e-06 | 0.0006198 |
75 | MULTICELLULAR ORGANISMAL SIGNALING | 11 | 123 | 9.99e-06 | 0.0006198 |
76 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 21 | 408 | 1.017e-05 | 0.0006228 |
77 | REGULATION OF CELL SUBSTRATE ADHESION | 13 | 173 | 1.073e-05 | 0.0006482 |
78 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 27 | 616 | 1.094e-05 | 0.0006524 |
79 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 36 | 957 | 1.147e-05 | 0.000667 |
80 | ENDOCHONDRAL BONE MORPHOGENESIS | 7 | 45 | 1.147e-05 | 0.000667 |
81 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 24 | 513 | 1.182e-05 | 0.0006791 |
82 | REGULATION OF MAP KINASE ACTIVITY | 18 | 319 | 1.294e-05 | 0.0007344 |
83 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 15 | 232 | 1.407e-05 | 0.0007885 |
84 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 37 | 1008 | 1.477e-05 | 0.0008084 |
85 | MUSCLE CELL DEVELOPMENT | 11 | 128 | 1.461e-05 | 0.0008084 |
86 | METANEPHRIC NEPHRON DEVELOPMENT | 6 | 32 | 1.617e-05 | 0.000875 |
87 | HEART PROCESS | 9 | 85 | 1.659e-05 | 0.0008873 |
88 | RESPONSE TO MECHANICAL STIMULUS | 14 | 210 | 1.929e-05 | 0.00102 |
89 | REGULATION OF JNK CASCADE | 12 | 159 | 2.239e-05 | 0.00117 |
90 | CIRCULATORY SYSTEM PROCESS | 19 | 366 | 2.392e-05 | 0.001223 |
91 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 11 | 135 | 2.412e-05 | 0.001223 |
92 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 17 | 303 | 2.418e-05 | 0.001223 |
93 | MUSCLE ORGAN DEVELOPMENT | 16 | 277 | 2.947e-05 | 0.001474 |
94 | NEPHRON DEVELOPMENT | 10 | 115 | 3.227e-05 | 0.001589 |
95 | PROTEIN AUTOPHOSPHORYLATION | 13 | 192 | 3.245e-05 | 0.001589 |
96 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 34 | 926 | 3.322e-05 | 0.00161 |
97 | DEVELOPMENTAL MATURATION | 13 | 193 | 3.426e-05 | 0.001643 |
98 | RESPONSE TO HORMONE | 33 | 893 | 3.843e-05 | 0.00178 |
99 | TUBE DEVELOPMENT | 24 | 552 | 3.863e-05 | 0.00178 |
100 | CARDIAC MUSCLE CELL ACTION POTENTIAL | 6 | 37 | 3.856e-05 | 0.00178 |
101 | REGULATION OF CELL MORPHOGENESIS | 24 | 552 | 3.863e-05 | 0.00178 |
102 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 13 | 197 | 4.24e-05 | 0.001934 |
103 | REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 6 | 38 | 4.513e-05 | 0.002039 |
104 | REGULATION OF CELL PROJECTION ORGANIZATION | 24 | 558 | 4.581e-05 | 0.00205 |
105 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 18 | 352 | 4.756e-05 | 0.002108 |
106 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 42 | 1275 | 4.901e-05 | 0.002151 |
107 | MEMBRANE DEPOLARIZATION DURING ACTION POTENTIAL | 6 | 39 | 5.256e-05 | 0.002203 |
108 | STRIATED MUSCLE CELL DIFFERENTIATION | 12 | 173 | 5.143e-05 | 0.002203 |
109 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 39 | 1152 | 5.189e-05 | 0.002203 |
110 | SKELETAL SYSTEM MORPHOGENESIS | 13 | 201 | 5.218e-05 | 0.002203 |
111 | REGULATION OF GTPASE ACTIVITY | 27 | 673 | 5.109e-05 | 0.002203 |
112 | ANGIOGENESIS | 16 | 293 | 5.778e-05 | 0.0024 |
113 | REGULATION OF TRANSMEMBRANE TRANSPORT | 20 | 426 | 6.046e-05 | 0.002489 |
114 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 22 | 498 | 6.435e-05 | 0.002626 |
115 | BONE MORPHOGENESIS | 8 | 79 | 6.768e-05 | 0.002738 |
116 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 23 | 541 | 7.854e-05 | 0.003124 |
117 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 23 | 541 | 7.854e-05 | 0.003124 |
118 | REGULATION OF ANATOMICAL STRUCTURE SIZE | 21 | 472 | 8.53e-05 | 0.003363 |
119 | MEMBRANE DEPOLARIZATION | 7 | 61 | 8.694e-05 | 0.003399 |
120 | BONE DEVELOPMENT | 11 | 156 | 9.079e-05 | 0.003491 |
121 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 19 | 404 | 9.011e-05 | 0.003491 |
122 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 35 | 1021 | 0.0001006 | 0.003837 |
123 | NEGATIVE REGULATION OF GENE EXPRESSION | 46 | 1493 | 0.0001039 | 0.003929 |
124 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 7 | 63 | 0.000107 | 0.004016 |
125 | PROTEIN PHOSPHORYLATION | 33 | 944 | 0.0001112 | 0.004139 |
126 | CARDIAC SEPTUM DEVELOPMENT | 8 | 85 | 0.0001141 | 0.004186 |
127 | REGULATION OF ION TRANSPORT | 24 | 592 | 0.0001142 | 0.004186 |
128 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 31 | 872 | 0.0001339 | 0.004868 |
129 | REGULATION OF RESPIRATORY SYSTEM PROCESS | 4 | 16 | 0.0001374 | 0.004957 |
130 | SKELETAL MUSCLE ORGAN DEVELOPMENT | 10 | 137 | 0.0001419 | 0.005079 |
131 | SKELETAL SYSTEM DEVELOPMENT | 20 | 455 | 0.0001474 | 0.005237 |
132 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 46 | 1517 | 0.0001501 | 0.005291 |
133 | REGULATION OF HEART RATE BY CARDIAC CONDUCTION | 5 | 30 | 0.0001523 | 0.00533 |
134 | CONNECTIVE TISSUE DEVELOPMENT | 12 | 194 | 0.0001536 | 0.005334 |
135 | NEGATIVE REGULATION OF PHOSPHORYLATION | 19 | 422 | 0.0001585 | 0.005463 |
136 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 11 | 167 | 0.0001663 | 0.005689 |
137 | MESONEPHROS DEVELOPMENT | 8 | 90 | 0.0001705 | 0.005792 |
138 | ORGAN GROWTH | 7 | 68 | 0.0001742 | 0.005811 |
139 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 24 | 609 | 0.0001748 | 0.005811 |
140 | REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 6 | 48 | 0.0001734 | 0.005811 |
141 | REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 9 | 116 | 0.0001921 | 0.006293 |
142 | REGULATION OF METAL ION TRANSPORT | 16 | 325 | 0.0001921 | 0.006293 |
143 | REGULATION OF CELLULAR RESPONSE TO STRESS | 26 | 691 | 0.0001961 | 0.006381 |
144 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 42 | 1360 | 0.0002024 | 0.006539 |
145 | REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 7 | 70 | 0.0002091 | 0.00671 |
146 | NEPHRON EPITHELIUM DEVELOPMENT | 8 | 93 | 0.0002142 | 0.006734 |
147 | REGULATION OF ION HOMEOSTASIS | 12 | 201 | 0.0002137 | 0.006734 |
148 | REGULATION OF BLOOD CIRCULATION | 15 | 295 | 0.0002142 | 0.006734 |
149 | NEGATIVE REGULATION OF CELL COMMUNICATION | 38 | 1192 | 0.0002221 | 0.006937 |
150 | PLASMA MEMBRANE ORGANIZATION | 12 | 203 | 0.0002341 | 0.007262 |
151 | EMBRYONIC DIGESTIVE TRACT DEVELOPMENT | 5 | 33 | 0.0002431 | 0.007492 |
152 | DIGESTIVE SYSTEM DEVELOPMENT | 10 | 148 | 0.0002665 | 0.008105 |
153 | BIOLOGICAL ADHESION | 34 | 1032 | 0.0002658 | 0.008105 |
154 | ACTIVATION OF MAPKK ACTIVITY | 6 | 52 | 0.0002714 | 0.008201 |
155 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 5 | 34 | 0.000281 | 0.008329 |
156 | KIDNEY VASCULATURE DEVELOPMENT | 4 | 19 | 0.0002809 | 0.008329 |
157 | RENAL SYSTEM VASCULATURE DEVELOPMENT | 4 | 19 | 0.0002809 | 0.008329 |
158 | REGULATION OF OSSIFICATION | 11 | 178 | 0.0002895 | 0.008526 |
159 | SKELETAL MUSCLE CELL DIFFERENTIATION | 6 | 53 | 0.0003017 | 0.008828 |
160 | CELL PART MORPHOGENESIS | 24 | 633 | 0.0003085 | 0.008971 |
161 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 8 | 99 | 0.0003292 | 0.00936 |
162 | POSITIVE REGULATION OF CELL ADHESION | 17 | 376 | 0.0003319 | 0.00936 |
163 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 10 | 152 | 0.0003302 | 0.00936 |
164 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 8 | 99 | 0.0003292 | 0.00936 |
165 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 8 | 99 | 0.0003292 | 0.00936 |
166 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 52 | 1848 | 0.0003406 | 0.009546 |
167 | REGULATION OF NEURON PROJECTION REGENERATION | 4 | 20 | 0.0003463 | 0.009649 |
168 | REGULATION OF MEMBRANE POTENTIAL | 16 | 343 | 0.0003507 | 0.009714 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | KINASE BINDING | 31 | 606 | 8.708e-08 | 5.843e-05 |
2 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 47 | 1199 | 1.41e-07 | 5.843e-05 |
3 | ENZYME BINDING | 60 | 1737 | 1.887e-07 | 5.843e-05 |
4 | REGULATORY REGION NUCLEIC ACID BINDING | 34 | 818 | 2.466e-06 | 0.0005727 |
5 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 19 | 328 | 5.114e-06 | 0.0009501 |
6 | IDENTICAL PROTEIN BINDING | 43 | 1209 | 6.257e-06 | 0.0009688 |
7 | PROTEIN HOMODIMERIZATION ACTIVITY | 30 | 722 | 9.958e-06 | 0.001322 |
8 | VOLTAGE GATED SODIUM CHANNEL ACTIVITY | 5 | 20 | 1.911e-05 | 0.002219 |
9 | MAP KINASE KINASE KINASE ACTIVITY | 5 | 22 | 3.155e-05 | 0.003257 |
10 | BINDING BRIDGING | 12 | 173 | 5.143e-05 | 0.004778 |
11 | GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 16 | 303 | 8.576e-05 | 0.006922 |
12 | TRANSCRIPTIONAL REPRESSOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 9 | 105 | 8.941e-05 | 0.006922 |
13 | BHLH TRANSCRIPTION FACTOR BINDING | 5 | 28 | 0.0001081 | 0.007459 |
14 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 25 | 629 | 0.0001124 | 0.007459 |
15 | TRANSCRIPTION FACTOR BINDING | 22 | 524 | 0.0001342 | 0.008309 |
16 | PROTEIN KINASE ACTIVITY | 25 | 640 | 0.0001471 | 0.008538 |
17 | ACTIN BINDING | 18 | 393 | 0.0001906 | 0.009717 |
18 | RECEPTOR SIGNALING PROTEIN SERINE THREONINE KINASE ACTIVITY | 8 | 92 | 0.0001987 | 0.009717 |
19 | MACROMOLECULAR COMPLEX BINDING | 43 | 1399 | 0.0001875 | 0.009717 |
20 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 11 | 172 | 0.0002152 | 0.009997 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | MEMBRANE REGION | 48 | 1134 | 9.635e-09 | 5.627e-06 |
2 | MEMBRANE MICRODOMAIN | 21 | 288 | 3.575e-08 | 1.044e-05 |
3 | PLASMA MEMBRANE RAFT | 10 | 86 | 2.389e-06 | 0.0004651 |
4 | ACTIN CYTOSKELETON | 22 | 444 | 1.136e-05 | 0.001327 |
5 | CELL JUNCTION | 41 | 1151 | 1.011e-05 | 0.001327 |
6 | PLASMA MEMBRANE REGION | 35 | 929 | 1.48e-05 | 0.00144 |
7 | BASAL PLASMA MEMBRANE | 6 | 33 | 1.948e-05 | 0.001625 |
8 | INTRINSIC COMPONENT OF PLASMA MEMBRANE | 51 | 1649 | 3.795e-05 | 0.002771 |
9 | SITE OF POLARIZED GROWTH | 11 | 149 | 5.995e-05 | 0.00389 |
10 | VOLTAGE GATED SODIUM CHANNEL COMPLEX | 4 | 14 | 7.769e-05 | 0.004125 |
11 | CELL SUBSTRATE JUNCTION | 19 | 398 | 7.401e-05 | 0.004125 |
12 | CELL CELL CONTACT ZONE | 7 | 64 | 0.0001184 | 0.00494 |
13 | POSTSYNAPSE | 18 | 378 | 0.0001178 | 0.00494 |
14 | NEURON PROJECTION | 33 | 942 | 0.0001069 | 0.00494 |
15 | ANCHORING JUNCTION | 21 | 489 | 0.0001395 | 0.005432 |
16 | SODIUM CHANNEL COMPLEX | 4 | 17 | 0.0001773 | 0.00647 |
17 | BASAL PART OF CELL | 6 | 51 | 0.0002436 | 0.008369 |
18 | NEURON SPINE | 9 | 121 | 0.0002639 | 0.008562 |
19 | BASOLATERAL PLASMA MEMBRANE | 12 | 211 | 0.0003334 | 0.009351 |
20 | CONTRACTILE FIBER | 12 | 211 | 0.0003334 | 0.009351 |
21 | SARCOLEMMA | 9 | 125 | 0.0003362 | 0.009351 |
22 | DENDRITE | 19 | 451 | 0.0003656 | 0.009704 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04380_Osteoclast_differentiation | 11 | 128 | 1.461e-05 | 0.002629 | |
2 | hsa04710_Circadian_rhythm_._mammal | 4 | 23 | 0.0006075 | 0.05467 | |
3 | hsa04722_Neurotrophin_signaling_pathway | 8 | 127 | 0.001698 | 0.0908 | |
4 | hsa00604_Glycosphingolipid_biosynthesis_._ganglio_series | 3 | 15 | 0.002018 | 0.0908 | |
5 | hsa04115_p53_signaling_pathway | 5 | 69 | 0.006932 | 0.1451 | |
6 | hsa04010_MAPK_signaling_pathway | 11 | 268 | 0.007388 | 0.1451 | |
7 | hsa04510_Focal_adhesion | 9 | 200 | 0.008399 | 0.1451 | |
8 | hsa04014_Ras_signaling_pathway | 10 | 236 | 0.008428 | 0.1451 | |
9 | hsa04530_Tight_junction | 7 | 133 | 0.008614 | 0.1451 | |
10 | hsa04151_PI3K_AKT_signaling_pathway | 13 | 351 | 0.008659 | 0.1451 | |
11 | hsa04144_Endocytosis | 9 | 203 | 0.00921 | 0.1451 | |
12 | hsa04514_Cell_adhesion_molecules_.CAMs. | 7 | 136 | 0.009675 | 0.1451 | |
13 | hsa04350_TGF.beta_signaling_pathway | 5 | 85 | 0.01619 | 0.2242 | |
14 | hsa04630_Jak.STAT_signaling_pathway | 7 | 155 | 0.01872 | 0.2406 | |
15 | hsa04360_Axon_guidance | 6 | 130 | 0.02598 | 0.3118 | |
16 | hsa00770_Pantothenate_and_CoA_biosynthesis | 2 | 16 | 0.03068 | 0.3452 | |
17 | hsa04672_Intestinal_immune_network_for_IgA_production | 3 | 49 | 0.05312 | 0.5519 | |
18 | hsa00532_Glycosaminoglycan_biosynthesis_._chondroitin_sulfate | 2 | 22 | 0.05519 | 0.5519 | |
19 | hsa00512_Mucin_type_O.Glycan_biosynthesis | 2 | 30 | 0.09505 | 0.9005 | |
20 | hsa04620_Toll.like_receptor_signaling_pathway | 4 | 102 | 0.1017 | 0.9152 | |
21 | hsa04920_Adipocytokine_signaling_pathway | 3 | 68 | 0.1143 | 0.9709 | |
22 | hsa04660_T_cell_receptor_signaling_pathway | 4 | 108 | 0.1187 | 0.9709 | |
23 | hsa04390_Hippo_signaling_pathway | 5 | 154 | 0.1305 | 0.9764 | |
24 | hsa04520_Adherens_junction | 3 | 73 | 0.1335 | 0.9764 | |
25 | hsa04145_Phagosome | 5 | 156 | 0.1356 | 0.9764 | |
26 | hsa00310_Lysine_degradation | 2 | 44 | 0.1773 | 1 | |
27 | hsa04973_Carbohydrate_digestion_and_absorption | 2 | 44 | 0.1773 | 1 | |
28 | hsa04110_Cell_cycle | 4 | 128 | 0.1829 | 1 | |
29 | hsa04512_ECM.receptor_interaction | 3 | 85 | 0.1834 | 1 | |
30 | hsa04012_ErbB_signaling_pathway | 3 | 87 | 0.1922 | 1 | |
31 | hsa00983_Drug_metabolism_._other_enzymes | 2 | 52 | 0.2279 | 1 | |
32 | hsa04912_GnRH_signaling_pathway | 3 | 101 | 0.2559 | 1 | |
33 | hsa04670_Leukocyte_transendothelial_migration | 3 | 117 | 0.3315 | 1 | |
34 | hsa03018_RNA_degradation | 2 | 71 | 0.3497 | 1 | |
35 | hsa04020_Calcium_signaling_pathway | 4 | 177 | 0.3688 | 1 | |
36 | hsa04664_Fc_epsilon_RI_signaling_pathway | 2 | 79 | 0.3994 | 1 | |
37 | hsa03008_Ribosome_biogenesis_in_eukaryotes | 2 | 81 | 0.4115 | 1 | |
38 | hsa04974_Protein_digestion_and_absorption | 2 | 81 | 0.4115 | 1 | |
39 | hsa04062_Chemokine_signaling_pathway | 4 | 189 | 0.4159 | 1 | |
40 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 3 | 136 | 0.4208 | 1 | |
41 | hsa04910_Insulin_signaling_pathway | 3 | 138 | 0.43 | 1 | |
42 | hsa04914_Progesterone.mediated_oocyte_maturation | 2 | 87 | 0.4472 | 1 | |
43 | hsa04640_Hematopoietic_cell_lineage | 2 | 88 | 0.453 | 1 | |
44 | hsa04210_Apoptosis | 2 | 89 | 0.4588 | 1 | |
45 | hsa04970_Salivary_secretion | 2 | 89 | 0.4588 | 1 | |
46 | hsa00240_Pyrimidine_metabolism | 2 | 99 | 0.5147 | 1 | |
47 | hsa04972_Pancreatic_secretion | 2 | 101 | 0.5254 | 1 | |
48 | hsa00230_Purine_metabolism | 3 | 162 | 0.5356 | 1 | |
49 | hsa04114_Oocyte_meiosis | 2 | 114 | 0.5911 | 1 | |
50 | hsa04270_Vascular_smooth_muscle_contraction | 2 | 116 | 0.6006 | 1 | |
51 | hsa04120_Ubiquitin_mediated_proteolysis | 2 | 139 | 0.6978 | 1 | |
52 | hsa04810_Regulation_of_actin_cytoskeleton | 3 | 214 | 0.7208 | 1 | |
53 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 2 | 168 | 0.7917 | 1 |